vTv Therapeutics (VTVT) News
NASDAQ: VTVTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
31.18+1.10 (+3.66%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
VTVT news summary
We found 3 recent headlines mentioning vTv Therapeutics (VTVT): 3 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, VTVT is up 3.66% at $31.18. The most recent story, "vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026", was published by GlobeNewswire on Oct 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest vTv Therapeutics headlines
- vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026New research spotlights hypoglycemia-related burdens in adults with type 1 diabetes using automated insulin delivery systems New research spotlights hypoglycemia-related burdens in adults with type 1…GlobeNewswire
- VTv's HPPD Receives FDA Orphan Drug Status For Sickle Cell Disease(RTTNews) - Wednesday, vTv Therapeutics Inc. (VTVT) said that the U.S. FDA granted Orphan Drug Status to HPPD (HPP8668) for the treatment of sickle cell disease.NasdaqVTVT, BRK.A
- vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell DiseaseMilestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatin Milestone supports partnering discussions…GlobeNewswire